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AbstrAct
We have developed a dual probe quantitative Pcr (qPcr) mini array enabling a more accurate analysis 
of the relationship between copy number variants (CNVs) and other genomic features in specific areas. We 
used it to map hemizygous microdeletion on human chromosome 7 around the elastin gene (ELN), which is 
the molecular basis of the Williams-Beuren syndrome (WBS). In two WBS patients, the haploid content of 
the elastin gene was ascertained previously by the fluorescence in-situ hybridization (FISH). Our dual-color 
qPCR assay used this information to normalize for DNA content in all tests. We mapped the extent of the 
deleted area using 10 loci spanning over 4 Mb. A border region containing the GTF2I gene, usually deleted 
in most cases, was found about 10 times amplified in both patients, suggesting an unusual type of the WBS 
genetic defect. This 10-WBS-loci-specific qPCR assay could be an affirmative diagnostic tool alternative to 
FISH. Due to low cost, it could be used as a screening test that would not only facilitate research on CNVs, 
but also allow early diagnosis of the disease, as well-timed diagnosis would benefit WBS children with ear-
lier proper health-care measures. (Int J Biomed Sci 2008: 4(3):100-109)
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INTRODuCTION
The Williams-Beuren syndrome (WBS) is a complex 
multisystemic developmental disorder caused by hemizy-
gous microdeletion around the elastin gene on chromo-
some 7. The WBS is characterized by a unique phenotype 
that typically includes dysmorphic cranio-facial features, 
supravalvular aortic stenosis (SVAS), hypertension, men-
tal retardation, premature aging of the skin, infantile hy-
percalcemia, tooth anomalies, and an unusual set of cog-
nitive and behavioral profiles (1-5). The clinical diagnosis 
is usually confirmed by fluorescent in situ hybridization 
(FISH) analysis showing hemizygous complement of the 
elastin gene.
The commonly deleted area on the chromosome 7 is 
designated the Williams-Beuren syndrome critical re-
gion (WBSCR) and includes over 35 genes, some without 
known function (Fig 1). While hemizygosity of the elastin 
gene is correlated with SVAS, hemideletion of other WB-
SCR genes is likely to be a contributing factor to diver-
sity of patients’ phenotypes. The most common deletion 
is about 1.55 Mb in size, and a larger one (about 1.84 Mb) 
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occurs in about 4% of the cases. Less than 1% was re-
ported for other abnormalities (6). However, these reports 
address only the cases in North America. It seems that 
the other unusual types of deletions are more common in 
other parts of the world. In the WBS critical region, dele-
tion borders contain low copy repetitive sequences (LCRs) 
that share about 95% sequence homology. In the figure 1, 
three LCRs were found in the WBSCR: the centromeric 
(LCRc), medial (LCRm) and telomeric (LCRt). The LCRs 
contain three different blocks of repetitive sequences (A, 
B and C), which are mixed between them (resulting with 
different order and/or orientation in each LCR), and con-
tain several genes including "Neutrophil cytosol factor 1" 
(NCF1), "general transcription factor II, i" (GTF2I), and 
"GTF2I repeat domain containing 2" (GTF2IRD2) genes 
and their look-alikes (Fig. 1). Apparently, this structure 
fuels genetic instability of this region, with the most com-
mon cause for deletion being unequal meiotic crossover 
(6). The borders for the common WBS deletion of 1.55 Mb 
were found to be variable within this area due to a large 
transitional potential of chromosomal breakpoints (up to 
143 Kb) (6). 
Another contributing factor to WBS like symptoms is 
the hemizygous inversion of the WBSCR, but not all carri-
ers are symptomatic (7). Inversions of the WBSCR in un-
affected parents predispose for WBS in children caused by 
hemideletion (8). Different types of inversions exist, and 
despite the lack of statistical evidence so far, as the inver-
sions are difficult to detect, it seems reasonable to assume 
that they could generate variability in WBS deletions apart 
from the most commonly observed ones. Recently, a wide 
variety of deletions ranging between 0.25 and 2.5 Mb in 
length was reported using quantitative PCR approach (9).
However, it is still unclear to what level various geno-
types play a role in the generation of diverse phenotypes 
of the disease. 
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Figure 1. Schematic representation of genetic loci on chromosome 7 used for WBS specific double qPCR assays. The qPCR loci used 
for making the WS-specific array of qPCR assays are listed at the bottom, together with their precise position from the beginning of the 
chromosome and STS references. Positions were according to numbering from CRA_TCAGchr7v2 database. The map is according to 
information from the NCBI database. ELN= the elastin gene.
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Advances in genomic screening technologies such as 
microchip are revealing structural changes in individual 
genomes due to copy number variations, inversions, dele-
tions or nucleotide polymorphisms (for a review see (10)). 
The areas of structural variants differ to a great extent, the 
smaller the area the more difficult for precise mapping. 
Thus, the microarray technology could only coarsely esti-
mate the WBS deleted region, and such analysis is always 
dependent on more reliable qPCR analyses. Similarly, the 
ELN FISH method is simple, but not so specific when it 
comes to mapping the deletion area. Here, we wished to 
complement the research in this field that could also ben-
efit affected individuals providing an earlier diagnosis, as 
well as to search for genes that can affect dental malfor-
mation or agenesis. We developed a 10-locus duplex qPCR 
assay spanning over 4.5 Mb around WBSCR to detect 
hemizygous deletions on chromosome 7.
MATeRIAlS AND MeTHODS
Patients and controls
Criteria for clinical diagnosis of WBS were previously 
reported (11). Diagnosis was supported by biomedical as-
sessment of patients in which the tests described in this 
manuscript provided a part. This work is a pilot study to 
provide feasibility of the method to embark on a larger 
genotype/phenotype analysis of craniofacial develop-
mental aberrations. We collected blood samples from two 
WBS patients at the TAKO-Centre, Lovisenberg Dia-
konale Hospital, The control DNA included persons not 
affected by this syndrome, used in studies as described 
previously (12, 13). All persons provided oral and written 
informed consent. 
the DNA analysis
DNA was isolated from frozen blood using DNA isola-
tion kit according to manufacturer’s protocol. The control 
DNA was from the sample #4035 described previously in 
several reports (12, 13).
The tests were done by Taqman real time PCR assay 
using MX4000 or MX3005 PCR machines and software 
(Stratagene, San Diego, USA). The primers and probes for 
the WBSCR region were designated WS-Dg1-5, WS-Dg7 
and WS-Dg9; the controls were WS-CEN, WS-TEL and 
WS-ELN (centromeric, telomeric and elastin). The re-
porter dyes were 5’ FAM, except for the WS-ELN probe, 
which was labeled with HEX. All probes had zero fluores-
cence quencher at the 3’ end. The double qPCR array kit 
consisted of a set of WS-ELN-2 primers and probe (HEX) 
supplemented with one of the above-mentioned sets of 
primers and FAM-labeled probes.
All assays were done in triplicates, and the software 
provided by the PCR equipment manufacturer calculated 
statistics.
We used the following sequences for primers and 
probes: 
The WS-DgCEN qPCR test detects DNA sequence 
tagged site (STS) GDB: 1317778 (locus AUTS2; Gen-
Bank acc. no.: AC_000068; UniSTS: 3517). The assem-
bly map of chromosome 7 from the Center for Applied 
Genomics at the Hospital for Sick Children in Toronto 
(annotation of CRA_TCAGchr7v2) places the primers 
and probes at about 69.57 Mb (Fig 1). The primers and 
reporter probe were:
Forward (DgCen1-fw): 5’-GCTATCTTCAGGTCTC 
TCTCCAAACAG (69.565692..668);
Reverse (DgCen1-rv): 5’-GCATGTGAAGAAGGCA 
GCTTT (69.565616..636);
Reporter (DgCen1-pb): 5’-FAM-TGGAACAATAAC 
ACCAGCGAGATGGGA (69.565665..639).
The WS-Dg1 qPCR test defines STS DNA sequence 
SHGC83093 (GenBank acc. no.: AC_000068; UniSTS: 
184651) located at about 70.38 Mb (Fig 1) on chromosome 
7 (CRA_TCAGchr7v2). The primers and reporter probes 
for the WS-Dg1 were:
Forward (Dg1-fw): 5’-GGAGATAGAGACCCCAT 
GTATTGACT (70.379116..091);
Reverse (Dg1-rv): 5’-GAAACTTGGTGAGTGCCT 
TCTGT (70.379036..058);
Reporter (Dg1-pb): 5’-FAM-TGGTAGCTCCAGT 
GGAAATGCCTGCT (70.379089..064).
The WS-Dg2 qPCR test detects STS D7S2025 (Gen-
Bank acc. no.: AC_000068; UniSTS: 38585), which is 
located at about 70.58 Mb on chromosome 7 (CRA_
TCAGchr7v2). The primers and reporter probes for the 
WS-Dg2 were:
Forward (Dg2-fw): 5’-GTCATAGGGACAGATTCC 
TCATGA (70.580143..166)
Reverse (Dg2-rv): 5’-GCATGAACTAATAAAGT 
AACAATTCACTCA (70.580222..193),
Reporter (Dg2-pb): 5’-FAM-TGACTCGGTGCCCTC 
CCTG (70.580168..186).
The WS-Dg3 qPCR test identifies sequence close 
to D7S1912 sequence (GenBank acc. no.: AC_000068; 
UniSTS: 17311), which occurs at two sites (Fig 1) about 
66.02 and 71.39 Mb on chromosome 7 (CRA_TCAG-
chr7v2). The primers and reporter probes for the WS-
Dg3 were:
•
•
•
•
•
•
•
•
•
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Forward (Dg3-fw): 5’-CATTCTCTCTGTCGTCTTC 
TGTCTCT (occurs twice: 66.025310..335; 71.38907 
9..054 Mb);
Reverse (Dg3-rv): 5’-GACCATGAACACCATCAA 
GTGAA (occurs at 2 sites: 66.025390..368; 71.38899 
9..021 Mb);
Reporter (Dg3-pb): 5’-FAM-CTTCTGAGATTG 
CCACGTGCAA (occurs at 2 sites: 66.025339..360 
and 71.389050..029).
The WS-Dg4 qPCR test defines sequence GDB: 
4585495, which occurs at three loci (Fig 1): tripartite 
motif-containing 74 (TRIM74), TRIM50, and TRIM73 
(GenBank acc. no.: AC_000068). On chromosome 7 
(CRA_TCAGchr7v2) the reporter sequence Dg4-pb (22-
mer) occurs at three sites, similarly as the reverse primer. 
However, since the Dg4-forward primer sequence occurs 
at the first (centromeric, TRIM74) and the last (telomeric, 
TRIM73) sites, the recognition by this assay is limited to 
the latter two loci (Fig 1).  The primers and reporter probes 
for the WS-Dg4 were:
Forward (Dg4-fw): 5’-CCTCTATTGCCCTCTTT 
AAGGTGTT (the first 4 nucleotides are not listed in 
the current database; sequence #5-25 occurs at 2 sites 
on chromosome 7: 71.766871..851 and 74.363921..941; 
it differs additionally at position 19 from the sequence 
at 72.069068..048); 
Reverse (Dg4-rv): 5’-CCCATCAATCGAGCATC 
TCA (occurs at 3 sites: 71.766804..823; 72.069001..020, 
and 74.363988..969);
Reporter (Dg4-pb): 5’-FAM-CCGTTGCCTCCTGTT 
TATTGAG (occurs at 3 sites: 71.766849..828, 
72.069046..025 and 74.363943..964).
The WS-Dg5 qPCR test defines RH79567 sequence at 
locus BCL7B (B-cell CLL/lymphoma 7B; GenBank ac-
cession: AC_000068; UniSTS: 92014), at about 72.28 Mb 
(Fig 1) on chromosome 7 (CRA_TCAGchr7v2). The prim-
ers and reporter probe were:
Forward (Dg5-fw): 5’-GGCAGGGATGCTGGAATG 
(72.284001-..018);
Reverse (Dg5-rv): 5’-GCCCTCAGCACACACATCT 
G (72.284071..052);
Reporter (Dg5-pb): 5’-FAM-CAGGTAGAGGTGAG 
AACAAAGCTGCGTGT (72.284020..048).
The WS-ELN-2 qPCR test detects STS sequence 
(SHGC-149516) in the last intron of the elastin gene (Gen-
Bank accession: AC005056; UniSTS: 177051) at about 
72.78 Mb (Fig 1) on chromosome 7 (CRA_TCAGchr7v2). 
The primers and probe were:
Forward (C2EL-fw; DgCtrl2_ELNgenefw): 5’-GAA 
•
•
•
•
•
•
•
•
•
•
GCCTTCCTGGATTTCTCAA (72.778989..968; [this 
sequence occurs also on chr 1]);
Reverse (C2EL-rv; DgCtrl2_ELNgenerv); 5’-TGCA 
ATGATGAAAGAAGCAGACA (72.778915..937);
Reporter (C2EL-pb; DgCtrl2_ELNgenepbH); 5’-
HEX-CTCCTTCTGGCCACCCCCAACC (72.7789 
65..944).
The WS-Dg7 primers and probe were selected from 
387-bp-long DNA sequence SHGC-2422 (locus GTF2I; 
GenBank accession: G10931; UniSTS: 37563) located at 
about 73.46 Mb on chromosome 7 (CRA_TCAGchr7v2), 
adjacent to D7S2714 and D7S1870. The primers and 
probe were:
Forward (Dg7d-fw): 5’-GCAGGCCCTCCCA 
TCAC (three sites on chromosome 7: 73.455950..934; 
86.235358..342; and 122.446747..731; single sites on 
chr 5, 9, 13 and 16, double sites on chr 1, 6, 8, 14, 15 
and X, three sites on chr 11, five sites on chromo-
somes 2, 3 and 12, and six sites on chr 4);
Reverse (Dg7d-rv): 5’-TGCTTCTGGTAGTGTT 
GGAGACA (chr 7: 73.455889..911);
Reporter (Dg7d-pb): 5’-FAM-ACAGCTGTGCCT 
GGTTGGCA (chr 7: 73.455932..913).
The WS-Dg9 qPCR assay defines two D7S3286 loci (in 
the WBSCR16 and WBSCR16-like genes; GenBank acc. 
no.: AC_000068; UniSTS: 254185), located about 73.79 
and 74.1 Mb (Fig 1) on chromosome 7 (CRA_TCAG-
chr7v2). The primers and reporter probe were:
Forward (Dg9-fw): 5’-TCCTGGCAAGGGTCTT 
TGAG (at 73.791169..150 & 74.121373..392);
Reverse (Dg9-rv): 5’-AGGCTGCGTCCCAAGTCA 
(at  73.791103..120 & 74.121439..422);
Reporter (Dg9-pb): 5’-FAM-CACAGCCACTGCCC 
CTGCTTGG (at 73.791148.127 and 74.121394..415).
The WS-DgTEL qPCR test defines STS D7S1580 
(GenBank accession: G00254; UniSTS: 39633) located 
between CCL26 and CCL24 genes (about 74.76 Mb) on 
chromosome 7 (CRA_TCAGchr7v2). The oligonucleotide 
set for the WS-DgTEL test comprised the following prim-
ers and probe:
Forward (DgTel2-fw): 5’-AGGACTCCCCCCAA 
ACATG (at 74.762421..439);
Reverse (DgTel2-rv): 5’-TGTGGTCAGGGAGGGTC 
TTG (at 74.762494..477);
Reporter (DgTel2-pb): 5’-FAM- CCAGTTTTGGC 
TTAACTTGGCTAC (at 74.762442..465).
Reactions contained about 25 ng of genomic DNA, and 
were performed in a final volume of 20 µl, using condi-
tions for Taqman PCR as instructed by the manufacturer 
•
•
•
•
•
•
•
•
•
•
•
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(ABI). Briefly, samples were incubated for 10 minutes at 
95 deg C to activate the enzyme, and then followed by 40 
cycles of 15 seconds at 94 deg C, and 45 seconds at 60 
deg C steps. The fluorescence, measured after each cycle, 
was analyzed with the latest version of MXpro software 
(Stratagene).
ReSulTS 
The STS database at the NCI/NCBI GenBank was 
searched for unique sequences that are present around the 
elastin gene in the Williams-Beuren syndrome critical 
region (WBSCR) on human chromosome 7. We initially 
selected 12; ten of which were within the WBSCR and 
two that were just a few Mb outside this area, altogether 
spanning over 4 Mb of DNA (Fig. 1). The primers and 
probes for qPCR were designed using Taqman technology, 
as it obviates the need for identification of amplicons. The 
fluorescent probes hybridize to specific PCR products sup-
plying the proof for amplifying the right DNA fragments, 
as determined by the increase of free fluorescent label 
after each cycle. According to the human genome data-
base (NCBI), our WBS specific qPCR array could detect 
unique STSs in the WBSCR, except for the WS-Dg3, WS-
Dg4 and WS-Dg-9 sets. The WS-Dg3 detects a duplicon 
(D7S1912) on chromosome 7, one between WS-Dg2 and 
WS-Dg4 (at 71.1 Mb), and the other 4 Mb centromeric to 
the WS-DgCEN probe (Fig. 1). The WS-Dg4 assay would 
detect only two (at 71.8 and 74.4 Mb) of three possible sites 
that this probe could identify in C blocks of the LCRs (Fig 
1), probably due to lack of forward-primer homologous 
sequence in medial C block (at 72.1 Mb; see materials 
and methods for explanation; not shown). The WS-Dg-9 
set detects two replicons (D7S3286) in the A blocks of 
medial and telomeric LCRs (Fig 1). Three probes (WS-
ELN-2, WS-Dg5 and WS-Dg7) detected single copy DNA 
sequences (in haploid genome) located in the WBS critical 
region. Outside the WBSCR, four probes (WS-DgCEN, 
WS-Dg1, WS-Dg2 and WS-DgTel) detected also single 
copy sequences (Fig 1). 
We first tested the WS-ELN-2 assay. To generate the 
standard curve for the elastin gene qPCR we used four ten-
fold dilutions of control DNA, all in triplicates (Fig 2A). 
The intensity of fluorescence (in combination with the fi-
delity of real time PCR amplification) was measured in 
order to calculate Ct values and initial DNA amount [ng] 
per tube using the software provided by the manufacturer. 
The DNA amount (previously determined by the spectro-
photometer) correlated linearly to DNA concentrations 
calculated by the software (Fig 2B). Using this standard 
curve, we measured DNA content of the control subject 
and two patients in a single dilution assay. The results for 
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Figure 2. A single qPCR assay for the elastin gene using WS-
ELN-2 probe: Amplification plots (qPCR) and the standard 
curve. A) The graph represents HEX fluorescence levels dur-
ing the 40-cycle amplification of the elastin gene with specific 
qPCR. The initial DNA quantity per sample was between 50 
and 0.05 ng, as ascertained by the spectrophotometer. The 
MX4000/MXPro software automatically calculates threshold 
cycle (Ct) using its algorithm. Values on the graph are linear, 
indicating good sensitivity within this range of detection of 
genomic DNA (0.05 ng - 50 ng) in order to calculate the elastin 
gene copy number; B) The standard curve for the WS-ELN-2 
probe, using control DNA in dilutions as in A (filled squares). 
The triangles depict values of DNA samples taken from two 
WBS patients and a single control individual, predicted by 
their Ct value. The position on the curve represents a certain 
copy number of this probe. Comparison between a patient and 
a control samples yields relative copy number per genome. The 
patients’ samples have half the copy number value of the elastin 
gene than the control sample. Thus the patients have haploid 
content of the elastin gene, which was corroborated by the in 
situ chromosomal hybridization (data not shown) during the 
initial diagnostic process.
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two patients varied between 9 and 13 ng per tube, despite 
an effort to equalize the input by spectrophotometer. This 
is likely due to a pipetting error, but it could be due to vari-
ations in DNA isolation procedure or simply an unknown 
biological variation. The control sample (having similar 
DNA input) showed about 30 ng per tube, which is more 
than a double of both patients' amount. The FISH indicat-
ed the haploid content of the elastin gene in both patients 
(data not shown). Thus, this difference in DNA quantity 
resembles the haploid or diploid content of the elastin gene 
in patients or control DNA samples, respectively.
Next, a single-probe qPCR results using control DNA 
showed that each of the FAM-labeled WS-Dg1,2,3,4,5,7,9, 
CEN and -TEL assays had similar linear correlation with 
DNA concentration (data not shown).
WBS specific qPCR assays consisted of a double-probe 
array of assays. Each assay had a set of primers and one 
FAM-labeled probe mixed with the elastin gene specific set 
of primers and its HEX-labeled probe (WS-ELN-2).  Mix-
ing two different sets of primers and probes in making an 
array of single-tube assays did not affect Ct linearity with 
DNA concentration in all possible cases, as shown in Fig 
3. Such conditions allowed the measurement of DNA con-
tent for each WS-Dg locus in samples from WBS patients 
(Fig 3). The fidelity of qPCR amplifications was between 
80 to 110% (Table 1).
In dual probe qPCR assays, the difference between 
DNA concentration measured using the elastin gene qPCR 
and that from another locus indicated the copy number 
difference between them. It is expressed in terms of mul-
tiples of the elastin gene copy number (Table 1). Since the 
former was known to be present in a single copy of pa-
tients’ DNA (as determined by FISH; data not shown), the 
copy number of the elastin gene locus was arbitrarily set 
to equal 1, in order to make Table 2. The corollary of this 
setup is that it normalizes for DNA input in all dual assays, 
thus avoiding pipetting error or biological variability in 
final calculations. The relative values are shown in Table 
1, and rounded up as to estimate probable copy numbers of 
indicated loci are summarized in Table 2.
In all dual assays, the ELN-2 assay consistently showed 
that the elastin gene copy number was always double in 
control than patients’ samples. The WS-Dg1 - 4 sequences 
were all similar between patients and the control, indicat-
ing that their copy number was unaffected in patients. The 
exception is perhaps WS-Dg4, which recognizes four (C 
block specific; Fig 1) sites, but could be recognizing 6 loci, 
provided a single-nucleotide mismatch in forward primer 
did not suppress its amplification (see Materials and meth-
ods). If so, then a third (0.33) Ct difference would indicate 
a loss of a single site and could possibly explain our find-
ings (Table 1). The WS-Dg5 locus (BCL7B) was found to 
be in the same copy number as the elastin gene in one, and 
probably in both patients; otherwise it is hard to explain 
two-thirds of a single copy number in the other patient 
(Table 1). The copy number of sequences detected by the 
WS-Dg9 probe appeared to be 4 in all tested individuals. 
Likewise, the control probes from telomeric (WS-DgTEL) 
and centromeric (WS-DgCEN) genetic areas were in dip-
loid number (Table 2). Interestingly, WS-Dg7 sequence 
was found hugely amplified in both patients. About 8-10 
fold increase in genomes was due to unknown reasons 
(Tables 1 and 2). However, it is tempting to speculate that 
these replicons might have substituted the deleted part of 
the chromosome 7. The latter could have been preferen-
tially selected during mitosis preserving perhaps the origi-
nal (undeleted) length of the chromosome.
In conclusion, the extent of the hemideletion can be ap-
proximately narrowed to an area between STS sequences 
Figure 3. A schematic representation of qPCR assays to detect 
hemizygous chromosomal microdeletion. The lines represent 
standard curves for all probes, each used in combination with 
a single elastin gene probe ELN (dual probe qPCR assays). The 
ELN probe standard curve is depicted with a full line, and WS-
Dg1,2,3,4,5,7, and 9 or WS-DgCEN and WS-DgTEL probes are 
represented with a dotted line. The points (control, patient 1 and 
2 DNA) were single measurements (in triplicates). The elastin 
probe (HEX; filled squares or triangles) was used in combi-
nation with each of the WS-Dg probes (FAM; open squares 
or triangles): The filled circles represent control (full line) or 
patient (dotted line) samples. The circles with a cross inside 
signify patients’ DNAs analyzed with the WBS-Dg7 (FAM) 
qPCR assay. These circles indicate  that patients’ samples have 
lower Ct compared to the star-like filled circle of the control 
one, indicating over 10-fold amplification of the genomic area 
detected by the WBS-Dg7 probe. Thus, patients have over 10 
times higher copy number variant of the WBS-Dg7 area than 
the control individual.
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Table 1. The specific dual  quantitative PCR analyses of the WBSCR
A. WS-elN-2a Ws-DgcENb CeN/elN-2
Sample CT (s.d.) PCR eff.
c ng (s.d.) CT (s.d.) PCR eff.
c ng (s.d.) [ng/ ng]
Patient1 25.92 (0.07) 106% 11.27 (0.57) 25.93 (0.07) 107% 22.50 (1.13) 2.00
Patient2 25.92 (0.04) - “ - 11.28 (0.35) 25.86 (0.08) - “ - 23.67 (1.40) 2.10
Control DNA 24.88 (0.04) - “ - 23.90 (0.73) 25.82 (0.06) - “ - 24.39 (1.02) 1.02
d
B. WS-elN-2a Ws-Dg1 b Dg1/elN-2
Sample CT (s.d.) PCR eff.
c ng (st. dev.) CT (s.d.) PCR eff.
c ng (st. dev.) [ng/ng]
Patient1 24.90 (0.03) 88% 11.80 (0.20) 24.80 (0.22) 97% 28.50 (4.37) 2.42
Patient2 25.25 (0.13) - “ - 9.47 (0.75) 25.11 (0.02) - “ - 22.80 (2.65) 2.41
Control DNA 23.90 (0.04) - “ - 22.10 (0.54) 24.83 (0.10) - “ - 27.70 (1.92) 1.25
d
C. WS-elN-2a WS-Dg2b Dg2/elN-2
Sample CT (s.d.) PCR eff.
c [ng/ng] CT (s.d.) PCR eff.
c ng (st. dev.) [ng/ng]
Patient1 27.71 (0.04) 103% 5.89 (0.17) 28.00 (0.12) 92% 9.83 (0.76) 1.67
Patient2 26.76 (0.07) - “ - 11.54 (0.54) 26.07 (0.03) - “ - 34.50 (0.69) 2.99
Control DNA 25.62 (0.01) - “ - 25.89 (0.27) 26.68 (0.01) - “ - 23.20 (0.12) 0.89
d
D. WS-elN-2a Ws-Dg3b Dg3/elN-2
Sample CT (s.d.) PCR eff.
c ng (s.d.) CT (s.d.) PCR eff.
c ng (s.d.) [ng/ng]
Patient1 24.62 (0.02) 98% 11.19 (0.16) 24.94 (0.06) 98% 20.38 (0.78) 1.82
Patient2 24.92 (0.06) - “ - 9.23 (0.39) 25.17 (0.04) - “ - 17.46 (0.42) 1.89
Control DNA 23.59 (0.06) - “ - 22.96 (0.99) 24.83 (0.05) - “ - 22.01 (0.73) 0.96
d
e. WS-elN-2a Ws-Dg4b Dg4/elN-2
Sample CT (s.d.) PCR eff.
c ng (s.d.) CT (s.d.) PCR eff.
c ng (s.d.) [ng/ng]
Patient1 23.38 (0.09) 106% 15.20 (0.99) 23.32 (0.11) 105% 25.64 (2.03) 1.69
Patient2 23.79 (0.10) - “ - 11.35 (0.82) 23.69 (0.04) - “ - 19.95 (0.57) 1.76
Control DNA 22.85 (0.04) - “ - 22.36 (0.68) 23.58 (0.21) - “ - 21.77 (3.29) 0.97
d
F. WS-elN-2a Ws-Dg5b Dg5/elN-2
Sample ng (s.d.) CT (s.d.) PCR eff.
c ng (s.d.) CT (s.d.) PCR eff.
c [ng/ng]
Patient1 27.76 (0.15) 97% 8.25 (0.83) 32.79 (0.29) 86% 2.85 (0.53) 0.35
Patient2 27.44 (0.14) - “ - 10.36 (0.95) 30.73 (0.21) - “ - 10.13 (1.34) 0.98
Control DNA 26.41 (0.06) - “ - 20.77 (0.86) 29.84 (0.12) - “ - 17.53 (1.30) 0.84
d
G. WS-elN-2a Ws-Dg7b Dg7/elN-2
Sample CT (s.d.) PCR eff.
c ng (s.d.) CT (s.d.) PCR eff.
c ng (s.d.) [ng/ng]
Patient1 26.91 (0.02) 112% 9.62 23.79 (0.22) 108% 81.50 8.5
Patient2 26.94 (0.05) - “ - 9.38 23.57 (0.24) - “ - 95.90 10.2
Control DNA 25.46 (0.06) - “ - 27.98 25.40 (0.29) - “ - 24.54 0.88
H. WS-elN-2a WS-Dg9b Dg9/elN-2
Sample CT (s.d.) PCR eff.
c ng (s.d.) CT (s.d.) PCR eff.
c ng (s.d.) [ng/ng]
Patient1 25.44 (0.05) 109% 12.74 (0.47) 23.81 (0.11) 114% 22.25 (1.83) 1.75
Patient2 25.72 (0.08) - “ - 10.36 (0.59) 23.84 (0.12) - “ - 21.76 (2.00) 2.10
Control DNA 25.50 (0.06) - “ - 25.35 (1.12) 23.56 (0.18) - “ - 26.99 (3.85) 1.06
d
I. WS-elN-2a Ws-DgtELb Tel/elN-2
Sample CT (s.d.) PCR eff.
c ng (s.d.) CT (s.d.) PCR eff.
c ng (s.d.) [ng/ng]
Patient1 25.27 (0.09) 81% 11.30 (0.62) 27.31 (0.15) 80% 18.34 (1.57) 1.62
Patient2 24.88 (0.00) - “ - 14.27 (0.95) 26.88 (0.21) - “ - 23.63 (2.90) 1.66
Control DNA 24.29 (0.06) - “ - 20.15 (0.62) 26.96 (0.10) - “ - 22.47 (1.32) 1.12
d
aThe elastin gene probe; bThe WBS diagnostic probes; cThe efficiency of the PCR reaction; dThe values represent accuracy of each dual PCR 
test. In dual PCR tests the ratio between calculated DNA contents of various WBS probes and the elastin gene probe should be theoretically 
1.00 in the control DNA samples as they have a diploid genome.
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detected by WS-Dg4 and WS-Dg7 probes (Fig. 1). This 
genetic area spans minimally 0.5 Mb to maximally 1.7 
Mb in length (Fig. 1), which is in agreement with previous 
reports on hemideletion in the WBSCR (6). The most un-
usual feature is the large copy number (8-10 times) of the 
genetic region around the WS-Dg7-probe that detects 9th 
intron of the GTF2I gene. 
DISCuSSION
The goal of our research is to correlate genotype and 
phenotype of the Williams-Beuren syndrome, especial-
ly in persons with dental abnormalities. As a first step, 
we developed a method for mapping the affected area 
in the genome. This is a potentially useful addition to 
a battery of known methods that are currently available 
to study copy number variation and other structural 
variants in the human genome (10). Today’s arsenal of 
molecular diagnostic tools includes a genomic microar-
ray with probes able to detect the level of unique genetic 
sequences (sequence tagged sites, STS) across all chro-
mosomes, and this information can be obtained in some 
specialized hospitals. However, these relatively high-
cost procedures suffer from the same shortcomings as 
the RNA microarray (expression data chips). Namely, 
the results are not conclusive, but informative, and need 
to be ascertained using more reliable and reproducible 
methods such as qPCR or fluorescent in-situ hybridiza-
tion (FISH). 
Our research could reveal genes important in patho-
genesis of the WBS, we established an accurate and fast 
method to diagnose the disease and coarsely map the most 
commonly hemideleted area on chromosome 7. Presently, 
diagnosis of the WBS involves FISH of chromosomes 
with the elastin gene as a probe, which is reliable, but 
not entirely specific. Namely, certain rare WBS cases are 
misdiagnosed (in which the elastin gene was not hemide-
leted). Our method involves quantifying parts of chromo-
somal DNA in order to distinguish between their haploid 
and diploid content in the genome (or higher copy number 
variants). For this, we created an array of qPCR tests to 
detect hemideletions causing WBS. 
Quantifying DNA in a plasmid, or in simpler genomes 
like in bacteria or viruses, is relatively straightforward 
method. However, complex genomes pose a larger prob-
lem, which the chance of cross-hybridization to similar 
DNA sequences. In addition, the WBSCR genetic area has 
its own structural complications.
The WBSCR has 3 large region-specific segmental du-
plications or low copy repetitive DNA elements (centro-
meric, medial and telomeric LCRs). Each LCR has three 
blocks denoted A, B and C. The block B includes genes 
GTF2I, NCF1 and GTF2IRD2 (or their look-alikes) that 
are oriented in the opposite direction in centromeric and 
telomeric LCRs, while the former and medial has the same 
orientation (Fig 1). These are thought to be the origins of 
genetic instability of the region, because the area between 
any two duplicated sequences that is oriented in the same 
direction can be deleted during unequal meiotic crossin-
gover (6). Thus, several theoretical possibilities exist for 
various kinds of deletions, and although the map of this 
area seems to be nearing completion (there is a gap of 50 
Kb centromeric to WBSCR16-like gene; around 74.1 Mb), 
the variety of WBS deletions can be generally grouped in 
two, a 1.55 and less common 1.84 Mb hemideletion. The 
rest show smaller deletions and partial syndrome features 
(6). Another anomaly is the inversion of the whole region 
between centromeric and medial LCRs with smaller dele-
tions in border segments (7). 
Therefore, the problem, apart from mapping positions 
of three LCRs in each patient, lies in detecting their copy 
number per genome. This area can be analyzed in each 
patient by recent genomic CNV microarray technology, 
however at considerable cost, as older techniques such as 
pulse-field electrophoresis, bacterial artificial chromosome 
(BAC), P1 phage, cosmid or other molecular cloning tech-
niques combined with fine mapping and DNA sequencing 
should be used to confirm the microarray results. If used to 
Table 2. Estimated copy number of loci spread over 4 Mb region 
encompassing the WBSCR
Loci controla Patient 1a Patient 2a
DgCEN 2 2 2
Dg1 2 2 2
Dg2 2 2 3
Dg3 4 4 4
Dg4 4 (6) 4 (5) 4 (5)
Dg5 2 1 1
Elastin (ELN-2) 2 1 1
Dg7 1 >8 >10
Dg9 4 4 4
DgTEL 2 2 2
The copy numbers of listed loci in two WBS patients and controls 
were estimated from measurements by dual qPCR in Table 1. aCopy 
number content per genome.
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screen a large number of samples, this procedure is obvi-
ously time-consuming and cost forbidding. A simpler ap-
proach, like random DNA (shotgun) sequencing would not 
work in this case, because LCRs would make the mapping 
partially incorrect, confusing and inconclusive. A possible 
solution to get around these problems is to measure the 
copy number with reliable quantitative test such as spe-
cific-probe-detecting qPCR, as has been recently shown 
by others (9). However, their range for mapping was re-
stricted to 2.5 Mb and perhaps some low copy repetitive 
features of the WBSCR were not anticipated to the full 
extent (i.e. some primers might detect multiple sites).  
We therefore made an array of PCR primers to quan-
tify several WBSCR loci, and identified specific probes 
to verify the origin of amplicons. In both WBS patients 
(Fig 2, Tables 1 and 2), we found that the region contain-
ing WS-Dg5 and WS-ELN-2 loci was deleted on one of 
the chromosomes 7 (Fig. 1), demonstrating the validity of 
the array. These tests now permit diagnosis of the Wil-
liams-Beuren syndrome in a simpler way even before the 
symptoms become evident for a great majority of patients 
(and their parents). Why is this important?
WBS patients present a number of clinical problems 
already in childhood, encompassing symptoms such as 
cardiovascular, connective tissue and neurodevelop-
mental abberations. Persons with WBS have typical yet 
subtle cranio-facial features. Most of them have mild to 
moderate levels of mental retardation. Cognitive abilities 
such as expressive language, auditory memory and face 
recognition are affected. There also may be impairment 
in visual-spatial abilities. In contrast, musical abilities or 
intense interest in music and performing arts are a dis-
tinguishing feature of the phenotype (1). Likewise, peo-
ple with WBS are extremely sociable, extroverted, and 
highly empathic in their responses to other people (14), 
but this sociability does not convert into more advanced 
social cognitive abilities (15). When psychological and 
social training starts early in childhood, mental abilities 
of WS patients seem to improve, and consequently lead 
to better socialization in adulthood (16). However, the 
WBS patients are not diagnosed early enough, because 
of unsuspecting, complex, and hardly recognizable mor-
phological features of the disease. 
At present, screening infants for a specific DNA deficit 
with a current state-of-the-art diagnostic procedure is cost 
forbidding, because the disease is rare and the procedure 
is lengthy and demanding.   The incidence of a syndrome 
or disorder depends on the accuracy of diagnosis. The in-
cidence of WBS is reported to be from 1 in 20.000 (17) to 
1 in 50.000  (18). A recent study estimates the incidence in 
the region of Hong Kong to be 1 in 23.500 live births (19). 
An epidemiological survey from Norway suggests that the 
prevalence could be as high as 1 in 7.500 (20). The WBS 
specific qPCR test developed by the present study could 
permit a cost-effective, non-invasive and rapid screening 
of newborns (or in pre-schooling environments) that does 
not imply highly specialized institutions. In addition, the 
test also makes available prenatal diagnosis, parental test-
ing and genetic counseling of potential parents in a faster 
and simpler context. While only the fetal diagnostic WBS 
test would be invasive (amniocentesis during pregnancy), 
the rest could be non-invasive, which might be an addi-
tional important advantage over the FISH method.
There are multiple research benefits (apart from the 
cost-effective one) that can be envisaged by the use of the 
here presented qPCR method. For example, about 80% of 
William’s syndrome patients have tooth abnormalities (11). 
Dental abnormalities range from enamel hypoplasia, mi-
crodontia and malocclusion, to total or partial lack of teeth 
in some patients (1, 11, 21). Perhaps the genes influenc-
ing certain aspects of tooth development might be found 
in the WBSCR. The search to find them might be helped 
by mapping the WBSCR using principles of the test de-
scribed in this study, as hemideleted areas of patients are 
not the same. It is corroborated by our preliminary find-
ings that in our partients the border area containing the 
GTF2I gene (its 9th intron) harboring marker D7S1870. 
The findings might eventually help in searching for novel 
treatments of patients with such dental abnormalities. By 
the same token, such testing might benefit clinical dentists 
and oral biologists in finding novel therapies in handling 
WBS symptoms like feeding difficulties, skeletal abnor-
malities, joint limitations and chronic otitis media. 
In conclusion, we report here an array of qPCR-based 
WBS specific assays detecting hemizygous microdeletion 
around the elastin gene together with an increased copy 
number of a small border region on human chromosome 7. 
The test would be useful in clinical medicine and research, 
especially for diagnostic purposes and genetic counseling 
of the disease. 
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